Drug Trial Radar · NCT06859788
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 29, 2025
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Sound Pharmaceuticals, IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Conditions
- Meniere's Disease
- Ménière's Disease
Interventions
EbselenDrug
Glutathione peroxidase mimetic
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: 180 and 360 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
The House Institute
Los Angeles, California
ENT and Allergy Associates of Florida
Boynton Beach, Florida
ENT and Allergy Associates of Florida
Delray Beach, Florida
Northwell Health
New Hyde Park, New York
ENT and Allergy Associates, LLP
New York, New York
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University of Texas Southwestern
Dallas, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.